Skip to Main Content

Paper Details

Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma.
Eur Urol
1
2022
Author NameAffiliation
Cristina Rodr??guez-AntonaSpanish National Cancer Research Centre
  • 1 - 1

Datasets

Release 1.2